SUBSCRIBE
SUBSCRIBE

Agenus Inc.

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Incyte Corporation, Agenus Strike $410 Million+ Immuno-Oncology Antibodies Pact
January 9, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
May 11, 2026
 · 
15 min read
Press Releases
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 5, 2026
 · 
3 min read
Press Releases
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
April 22, 2026
 · 
5 min read
Press Releases
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 21, 2026
 · 
7 min read
Press Releases
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
April 3, 2026
 · 
4 min read
Press Releases
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
April 2, 2026
 · 
6 min read
Press Releases
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
March 27, 2026
 · 
4 min read
Press Releases
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
March 18, 2026
 · 
5 min read
Press Releases
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
March 16, 2026
 · 
12 min read
Press Releases
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
March 10, 2026
 · 
6 min read
Load More